Summary
Busulphan levels in plasma were measured in 27 patients during conditioning therapy (1 mg/kg×4 for 4 days) before bone marrow transplantation. The mean minimal concentration found in children aged <5 years (237 ng ml−1) was lower than that observed in adults or older children (607 and 573 ng ml−1, respectively). The AUC for the last dose was significantly lower in young children (2,315 h ng ml−1) than in adults or older children (6,134 and 5,937 h ng ml−1, respectively). The elimination half-life for the last dose in young children was shorter (2.05 h) than that in either adults (2.59 h) or older children (2.79 h). When the AUC was normalized for body surface area, the difference between young children and the other groups was smaller but remained statistically significant. The total body clearance was significantly higher in young children (7.3 ml min−1 kg−1) as compared with both older children and adults (3.02 and 2.7 ml min−1 kg−1, respectively). The plasma levels of busulphan showed circadian rhythmicity, especially in young children. The concentration measured during the night in some patients was up to 3-fold that observed during daytime. We conclude that the busulphan dosage for children must be reconsidered and that further studies are urgently needed to develop an optimal therapy.
Similar content being viewed by others
Abbreviations
- AML:
-
acute myeloblastic leukemia
- ALL:
-
acute lymphatic leukemia
- AUL:
-
acute undifferentiated leukemia
- ABMT:
-
autologous bone marrow transplantation
- BMT:
-
allogeneic bone marrow transplantation
References
Appelbaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA, Crowley J, Deeg HJ, Fefer A, Greenberg PD, Kadin M, Smith W, Stewart P, Sullivan K, Storb R, Weiden P (1984) Bone marrow transplantation or chemotherapy after remission induction for adults with acute non-lymphoblastic leukemia. Ann Int Med 101: 581
Crom WR, Glynn-Barnhart MA, Rodman JH, Teresi ME, Kavanagh RE, Christensen ML, Relling MV, Evans WE (1987) Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 12: 168
Evans WE, Relling MV (1989) Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16: 327
Faulder CG, Hirrell PA, Hume R, Strange RC (1987) Studies of the development of glutathione S-transferase in human liver, adrenal, kidney and spleen. Biochem J 241: 221
Friis-Hansen B (1961) Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 28: 169
Goldstone AH (ed) (1986) Autologous bone marrow transplantation. Clin Haematol 15: 1
Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T-L, Saral R, Santos GW, Colvin OM (1989) Pharmacokinetics of busulphan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25: 55
Grochow LB, Krivit W, Whitley CB, Blazar B (1990) Busulfan disposition in children. Blood 75: 1723
Hassan M, Ehrsson H (1983) Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 277: 374
Hassan M, Ehrsson H (1987) Metabolism of [14C]-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 12: 71
Hassan M, Öberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Tötterman T, Eksborg S, Simonsson B (1989) Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 36: 525
Hobbs JR, Hugh-Jones K, Shaw PJ, Downie CJC, Williamson S (1986) Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant 1: 201
Hrushesky WJM (1985) Circadian timing of cancer chemotherapy. Science 228: 73
Levi F, Mechkouri M, Roulon A, Bailleul F, Horvath C, Reinberg A, Mathe G (1985) Circadian rhythm in tolerance of mice for etoposide. Cancer Treat Rep 69: 1443
Marks V, English J, Aherne W, Arendt J (1985) Chronopharmacology, Clin Biochem 18: 154
Maxwell GM (1989) Paediatric drug dosing: body weight versus surface area. Drugs 37: 113
Minors DS (1985) Chronobiology: its importance in clinical medicine. Clin Sci 69: 369
Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbien GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart RK, Yeager AM (1983) Marrow transplantation for acute non-lymphoblastic leukemia after treatment with busulphan and cyclophosphamide. Engl J Med 309: 1347
Vassal G, Gouyette A, Hartman O, Pico JL, Lemerle J (1989) Pharmacokinetics of high-dose busulphan in children. Cancer Chemother Pharmacol 24: 386
Wang Y-M, Sutow WW, Romsdahl MM, Perez C (1979) Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. Cancer Treat Rep 63: 405
Woods WG, O'Leary M, Nesbit ME (1981) Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr 98: 642
Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE (1983) Bleomycin disposition in children with cancer. Clin Pharmacol Ther 33: 668
Author information
Authors and Affiliations
Additional information
This work was supported by grant 2805-B90-01X from the Swedish Cancer Society
Rights and permissions
About this article
Cite this article
Hassan, M., Öberg, G., Bekassy, A.N. et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother. Pharmacol. 28, 130–134 (1991). https://doi.org/10.1007/BF00689702
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00689702